Product Description
an anthracycline similar to doxorubicin. For metastatic breast cancer. GPX-100 is unique among anthracyclines because it is not converted to doxorubicinol during metabolism in the body. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00123877)
Mechanisms of Action: TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gem
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Breast Cancer
Phase 1: Anal Cancer|Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
GPX-100-003 | P2 |
Terminated |
Breast Cancer |
None |
|
CDR0000066409 | P1 |
Completed |
Anal Cancer|Breast Cancer |
None |